The FTSE 100 ended Monday’s trading session slightly lower, closing down by 10.35 points, or 0.1%, at 10,857.70. This downturn was largely influenced by a significant decline in AstraZeneca shares as discussions of a potential merger with US-based Bristol-Myers Squibb sparked concern among investors. Meanwhile, the FTSE 250 managed to gain 249.75 points, a rise of 1.0%, while the AIM All-Share increased by 6.06 points, or 0.8%.
AstraZeneca’s Setback
AstraZeneca, the second-largest company by market capitalisation on the FTSE 100, saw its stock plunge by 9.0% following reports of merger talks with Bristol-Myers, valued at a staggering $400 billion. If realised, this deal would position the new entity as the world’s fourth-largest pharmaceutical company, trailing only Eli Lilly, Johnson & Johnson, and AbbVie.
Michael Leuchten, an analyst at Jefferies, expressed confusion regarding the merger, stating, “Given the strength of AstraZeneca’s growth and innovation profile, we are a bit perplexed by the news.” He further noted that while financial benefits could arise from such a merger, AstraZeneca’s robust performance does not necessitate “financial engineering.”
Bank of America’s Sachin Jain echoed this sentiment, suggesting that investor concerns may stem from a perceived lack of confidence in AstraZeneca’s future prospects.
European Markets Brighten
While the FTSE 100 struggled, other European markets experienced positive momentum. The CAC 40 in Paris rose by 1.2%, and the DAX 40 in Frankfurt climbed by 1.5%. In the United States, the stock market also saw gains, with the Dow Jones Industrial Average increasing by 1.0%, the S&P 500 rising by 1.1%, and the Nasdaq Composite up by 1.8%.
These gains were buoyed by a dip in oil prices, with Brent crude for October delivery trading lower at $83.92 a barrel, down from $90.12 just a few days prior. This decline followed comments from US President Donald Trump, who indicated a pause on potential military actions against Iran, although Iranian officials later denied any ongoing negotiations with the US.
Kathleen Brooks, research director at XTB, pointed out that falling oil prices could alleviate inflation concerns and potentially temper rising bond yields, which had seen a sharp increase in the previous week.
UK Manufacturing Growth Continues
In the UK, manufacturing growth sustained momentum through July, albeit at a slower pace. The S&P Global UK Manufacturing Purchasing Managers’ Index (PMI) dropped to 51.9, down from June’s 52.5, falling short of the preliminary estimate of 52.8. Despite this, the sector remains in expansion territory, indicating ongoing resilience.
The pound traded at $1.3425 on Monday afternoon, a slight decline from $1.3463 at the end of last week, and similarly fell against the euro to €1.1669 from €1.1702.
Lower bond yields in London provided a boost to housebuilders, with Barratt Developments up by 3.8%, Persimmon increasing by 2.2%, and Vistry soaring by 8.0%. Analyst David Adlington from JPMorgan remarked that expectations for the sector are low ahead of results, though he noted a generally positive tone in commentary thus far this earnings season.
Notable Stock Movements
On the FTSE 100, Barratt Developments led the gainers, rising by 11.20p to 304.50p, followed by Metlen Energy & Metals, Rentokil Initial, Smith & Nephew, and ICG, which all saw increases. Conversely, AstraZeneca topped the list of decline with a drop of 1,132.00p to 11,500.00p. Other notable fallers included IG Group, Coca-Cola HBC, British American Tobacco, and Intercontinental Hotels Group.
On the FTSE 250, Clarkson shares surged by 9.0% after the company announced it expects to exceed market expectations for the full year, driven by a strong first half influenced by disruptions in the Strait of Hormuz, a critical shipping route affected by geopolitical tensions.
Gold prices also saw a decline, trading at $4,036.96 per ounce, down from $4,041.68 the previous Friday.
Why it Matters
The fluctuations in the FTSE 100 highlight the sensitive nature of market sentiment, particularly in response to corporate developments such as AstraZeneca’s merger talks. This scenario underscores the delicate balance investors must navigate between potential growth opportunities and inherent risks. As geopolitical factors continue to unfold, the impact on oil prices and inflation could influence wider economic conditions, shaping investment strategies in the coming months.